TV

The Apothecary Diaries Live-Action Series Is Coming to Prime Video in 2028

Mana Ashida will play Maomao in a live-action Apothecary Diaries series from TOHO and Amazon MGM Studios, premiering on Prime Video in 2028.

By September 5, 2026

Prime Video is adapting one of the last few years’ biggest anime hits into a live-action series. Mana Ashida will play Maomao, the show’s poison-obsessed lead. In fact, she’s said the role is one she’s dreamed of for years. The series premieres on Prime Video in 2028.

Mana Ashida Steps Into Maomao’s Shoes

Ashida is a former child star now in her twenties. She grew up reading the source novels. She says she poured everything into understanding the character before landing the part. Original author Natsu Hyuga has already backed the casting publicly, saying the role felt safe the moment producers picked Ashida. So far, producers haven’t announced who will play Jinshi, the palace official who becomes Maomao’s investigative partner.

A TOHO and Amazon MGM Studios Co-Production

Meanwhile, TOHO and Amazon MGM Studios are co-producing the series together. Yuki Saito will direct, and Erika Yoshida is writing the screenplay. Prime Video will stream it exclusively worldwide. As a result, a major domestic Japanese studio and an international streamer are backing the same live-action swing.

The Story Getting the Live-Action Treatment

The Apothecary Diaries follows Maomao, an apothecary sold into servitude at the emperor’s palace. In particular, she ends up solving mysteries and court intrigue alongside a handsome, unusually perceptive official. The novels spawned a manga and a widely acclaimed anime adaptation. That franchise built a big enough audience that a live-action version felt inevitable. Still, whether it can capture the same tone in live action remains the open question for 2028.

Source: Anime Corner

Related Stories

Join the conversation

Be kind. Be curious. No fandom wars — we're all here because we love this stuff.

Leave a Reply

Discover more from The Nerd Wire

Subscribe now to keep reading and get access to the full archive.

Continue reading